Document Detail

Expression patterns of WT1 and PRAME in acute myeloid leukemia patients and their usefulness for monitoring minimal residual disease.
MedLine Citation:
PMID:  18950857     Owner:  NLM     Status:  MEDLINE    
Both WT1 and PRAME are highly expressed in acute myeloid leukemia (AML) patients. To assess the efficacy of their simultaneous detection for the purpose of monitoring minimal residual disease (MRD), we used real-time quantitative RT-PCR to quantify both WT1 and PRAME transcript levels in the bone marrow of 204 newly diagnosed AML patients, and 21 patients were serially monitored for a median of 11 months. The 22 normal bone marrow samples which served as controls collectively expressed low levels of WT1 and PRAME. An increase of >1-log over the upper limit of normal bone marrow was defined as positive. The positive rates of WT1 and PRAME for all patients were 79.2% and 55.4%, respectively. For the 108 patients lacking a specific fusion gene, the positive rate of WT1 was significantly higher than that of PRAME (76.9% vs. 35.2%, P<0.001). PRAME was positive in 9/25 WT1 (-) patients and the log increase of PRAME was higher than that of WT1 in 12/83 WT1 (+) patients. Dynamic patterns of WT1 and PRAME during follow-up showed that a consistent elevation or a rise over time to exceed the normal range predicted clinical relapse. The exception was that one patient's WT1 significantly decreased at relapse compared to diagnosis. Therefore, a simultaneous detection of WT1 and PRAME might not only provide AML patients with either a positive or a more sensitive molecular marker for MRD monitoring. Moreover, it might also avoid false negativity in the case of expression alteration.
YaZhen Qin; HongHu Zhu; Bin Jiang; JinLan Li; XiJing Lu; LingDi Li; GuoRui Ruan; YanRong Liu; ShanShan Chen; XiaoJun Huang
Related Documents :
1961037 - Cytogenetic and clonal culture evaluation after response to low dose ara-c in myelodysp...
17208297 - Bcr-abl mutant kinetics in cml patients treated with dasatinib.
12783377 - The cytogenetic response as a surrogate marker of survival.
9674747 - Novel enzymatic abnormalities in aml and cml in blast crisis: elevated leucocyte leukot...
3886067 - Ultrasonography, hida scintigraphy or both in the diagnosis of acute cholecystitis?
154397 - Comparative neuropsychological study of the changes in different programmed activities ...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2008-10-23
Journal Detail:
Title:  Leukemia research     Volume:  33     ISSN:  1873-5835     ISO Abbreviation:  Leuk. Res.     Publication Date:  2009 Mar 
Date Detail:
Created Date:  2009-01-27     Completed Date:  2009-02-27     Revised Date:  2009-04-06    
Medline Journal Info:
Nlm Unique ID:  7706787     Medline TA:  Leuk Res     Country:  England    
Other Details:
Languages:  eng     Pagination:  384-90     Citation Subset:  IM    
Laboratory of Cellular and Molecular Biology, Peking University Institute of Hematology, Peking University People's Hospital, 11 Xi-zhi-men South Street, Beijing 100044, People's Republic of China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Antigens, Neoplasm / analysis,  genetics*
Bone Marrow / chemistry
Case-Control Studies
Child, Preschool
Leukemia, Myeloid, Acute / genetics*
Middle Aged
Neoplasm, Residual / diagnosis*,  genetics
Reverse Transcriptase Polymerase Chain Reaction
Tumor Markers, Biological / analysis
WT1 Proteins / analysis,  genetics*
Young Adult
Reg. No./Substance:
0/Antigens, Neoplasm; 0/PRAME protein, human; 0/Tumor Markers, Biological; 0/WT1 Proteins
Comment In:
Leuk Res. 2009 May;33(5):603-4   [PMID:  19269525 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Time-course analyses addressing the acquisition of DBA lectin reactivity in mouse lymphoid organs an...
Next Document:  Families who begin versus decline therapy for children who are sexually abused.